SCHEMBL8539498

SCHEMBL8539498

CCc1ccc([C@H]2C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]3CCC4=CC5(CC[C@@H]4[C@H]32)SCCS5)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK1 Q15118 2/20 0.37
▸ PDK2 Q15119 2/20 0.37
▸ PDK3 Q15120 2/20 0.37
▸ PDK4 Q16654 2/20 0.37
▸ ESR1 P03372 10/20 0.36
▸ ESR2 Q92731 7/20 0.34
▸ LMNA P02545 3/20 0.34
▸ HSD17B10 Q99714 3/20 0.34
▸ TSHR P16473 2/20 0.34
▸ SLC22A1 O15245 2/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ SHBG P04278 2/20 0.34
▸ SERPINA6 P08185 2/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ MAPT P10636 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20048226 0.89 ESR1 (0.37) PDK1PDK2PDK3PDK4ESR1
SCHEMBL21143415 0.89 ESR1 (0.37) PDK1PDK2PDK3PDK4ESR1
SCHEMBL20048225 0.89 ESR1 (0.37) PDK1PDK2PDK3PDK4ESR1
SCHEMBL23131064 0.89 PGR (0.43) PDK1PDK2PDK3PDK4ESR1
SCHEMBL20048083 0.89 PGR (0.43) PDK1PDK2PDK3PDK4ESR1
SCHEMBL20048080 0.89 PGR (0.43) PDK1PDK2PDK3PDK4ESR1
SCHEMBL9019868 0.88 PDK1 (0.36) PDK1PDK2PDK3PDK4ESR1
SCHEMBL9019762 0.87 PGR (0.41) PDK1PDK2PDK3PDK4ESR1
SCHEMBL22861582 0.87 PGR (0.41) PDK1PDK2PDK3PDK4ESR1
SCHEMBL21143403 0.86 PDK1 (0.39) PDK1PDK2PDK3PDK4ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5843933-A 11β-aryl-4-estrenes, process for their production as well as their use as pharmaceutical agents SCHERING AKTIENGESELLSCHAFT (DE) 1998-12-01 — — US disclosed
US-5728689-A ANTIGESTAGENIC EFFECT SCHERING AKTIENGESELLSCHAFT (DE) 1998-03-17 — — US disclosed
EP-0404283-B1 11-Beta-aryl-4-estrene, method for its production and its use as a medicine SCHERING AG (DE) 1996-05-08 — — EP disclosed
EP-0404283-A2 11-Beta-aryl-4-estrene, method for its production and its use as a medicine SCHERING AKTIENGESELLSCHAFT (DE) 1990-12-27 — — EP disclosed
Send feedback